Introduction
Skin provides the largest immunity barrier because disordered immune responses result in a large variety of inflammatory skin diseases, including psoriasis, among others (Kupper and Fuhlbrigge, 2004) . The causes of psoriasis can be genetic, infectious, or environmental stimuli (Nestle et al., 2009; Cojocaru et al., 2010) . Cytokines released from Th1 and Th17 cells are believed to facilitate immunopathogenesis in immune-mediated psoriasis by inducing keratinocytes to generate inflammatory antimicrobial peptides, cytokines, and chemokines (Nestle et al., 2009; Zaba et al., 2009) . Recent investigations of psoriasis have focused primarily on the pathogenic role of Th17 cells (Krueger et al., 2007; Zheng et al., 2007; Steinman, 2010) . However, the levels of interferon (IFN)-γ in serum are positively correlated with disease severity in psoriasis (Szegedi et al., 2003; Abdallah et al., 2009; Takahashi et al., 2010) . Notably, IFN-γ-regulated gene expression is pivotal in psoriasis, and IFN-γ receptors (IFNGR) 1 and 2 are overexpressed in psoriatic peripheral blood mononuclear cells; additionally, the activation of signal transducer and activator of transcription (STAT) 1 has been identified in psoriatic skin lesions (Yao et al., 2008) . These results suggest an important role for IFN-γ, a Th1 cytokine, in the progression of skin inflammation.
IFN-γ belongs to a family of type II IFN cytokines that are released from Th1, natural killer (NK), and NKT cells, and it promotes anti-microbial responses, antigen processing, inflammation, growth suppression, cell death, tumor immunity, and autoimmunity (Platanias, 2005; Schoenborn and Wilson, 2007; Saha et al., 2010) . After binding to IFNGR, IFN-γ activates Janus kinase (Jak) 1 and Jak2 sequentially. Jak1 then induces STAT1 binding to IFNGR1 followed by Jak2-mediated STAT1 phosphorylation at the tyrosine residue 701 (Tyr701) (Bach et al., 1997; Ramana et al., 2002) . The activated STAT1 translocates to the nucleus and is necessary for the transactivation of pro-inflammatory molecules, including tumor necrosis factor-α, IFN-γ-induced protein 10, monocyte chemotactic protein-1, regulated upon activation, normal T-cell expressed, and intercellular adhesion molecule 1 Furthermore, the pathogenic role of IFN-γ signaling has been demonstrated in murine psoriasis-like skin inflammation (Arakura et al., 2007; Sarra et al., 2011) .
Glycogen synthase kinase (GSK)-3, a serine/threonine kinase, positively regulates multiple inflammatory diseases including sepsis, arthritis, colitis, and multiple sclerosis by influencing several critical transcription factors, such as NF-κB, nuclear factor of activated T cells, and STATs (Beurel et al., 2010; Kai et al., 2010; Wang et al., 2011) . Recent studies suggest that GSK-3 facilitates IFN-γ-mediated inflammation by mediating STAT1 activation (Tsai et al., 2009 ). Furthermore, GSK-3 facilities the Con A-induced IFN-γ-mediated immune hepatic injury by promoting STAT1 activation and the nuclear translocation of T-box transcription factor TBX21 (Tsai et al., 2011) . We therefore hypothesized that GSK-3 may facilitate IFN-γ-mediated skin inflammation. The model of inflammation used in this study was cutaneous inflammation induced using 12-O-tetradecanoylphorbol -13-acetate (TPA) treatment on rodent ears. TPA-induced acute skin inflammation causes ear edema and inflammatory infiltration. Long-term treatment with TPA induces skin epidermal hyperproliferation, dermal immune cell infiltration, and angiogenesis (De Vry et al., 2005; Park et al., 2011) . In this study, we investigated the role of GSK-3 in TPA-induced skin inflammation in vivo and the role of IFN-γ signaling in epidermal keratinocytes in vivo and in
vitro.
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Methods
Drugs and Reagents
TPA and GSK-3 inhibitor 6-bromoindirubin-3'-oxime (BIO) were purchased from Sigma-Aldrich (St. Louis, MO). Recombinant human IFN-γ was obtained from PeproTech (Rocky Hill, NJ). DAPI (4', 6-diamidino-2-phenylindole), and mouse anti-β-actin mAb were obtained from Sigma-Aldrich. Alex Fluor 488-labeled anti-mouse CD45, CD3ε, Gr-1, CD54, or CD31 and anti-mouse T-box transcription factor Tbx21 (T-bet) were obtained from BioLegend (San Diego, CA). Alexa Fluor 488-or 594-labeled and horseradish peroxidase (HRP)-conjugated goat anti-mouse, goat anti-rabbit, goat anti-rat, and donkey anti-goat IgG were from Invitrogen (Carlsbad, CA). The antibody for mouse signal transducers and activators of transcription (STAT) 1, phospho-glycogen synthase (GS, S641), and glycogen synthase kinase (GSK)-3β were obtained from Cell Signaling Technology (Beverly, MA).
Anti-mouse phospho-STAT1 (Y701), phospho-GSK-3α/β (Y279/Y216), and Ki-67 antibodies were obtained from Abcam (Cambridge, MA). Anti-GSK-3α/β was obtained from Santa Cruz (Santa Cruz, CA). Rat mAb targeted against mouse IFN-γ was obtained from Bender MedSystems (Burlingame, CA). Anti-mouse Gr-1 neutralizing Ab (clone RB6-8C5) was obtained from eBioscience (San Diego, CA).
Animal Treatment
The eight-to twelve-week-old progeny of wild type C57BL/6 mice and IFNGR1-deficient (Ifngr1 -/-) mice on a C57BL/6 background were purchased from the Jackson Laboratory (Bar Harbor, ME). They were fed standard laboratory chow and water ad libitum in the Laboratory Animal Center of the National Cheng Kung University. The animals were raised and cared for according to the guidelines set by the National Science Council, Taiwan. 
Immunohistochemistry and Immunostaining
All tissue sections were deparaffinized, rehydrated, incubated with 3% H 2 O 2 in methanol for 15 min, and subjected to heat-induced antigen retrieval by autoclaving them for 5 min in 10 mM citric acid buffer (pH 6.0). Following 2 washes in PBS, the tissue sections and cells were mixed with primary antibodies in antibody diluents (DAKO Corporation, Carpinteria, CA, USA) and incubated at 4°C overnight. The following day, the samples were washed with PBS and then incubated with or without HRP-and Alexa Fluor 488-or 594-labeled secondary antibodies at room temperature for 1 h. For immunohistochemistry, sections were washed with PBS, developed using AEC substrate (DAKO Corporation), counterstained with hematoxylin (Sigma-Aldrich), and visualized using an inverted microscope (IX71; Olympus, Tokyo, Japan). For immunostaining, sections and cells were washed with PBS and visualized using a DP70 camera and a fluorescent right BX51 microscope (Olympus, Tokyo, Japan) or a linear sequential C1Si laser scanning head and an Eclipse TE2000-E inverted microscope (Nikon Corp., Tokyo, Japan). DAPI (1:200; Sigma-Aldrich) was added for nuclear counter-staining and was applied at room temperature for 10 min. The confocal images were captured in a single
x-y scan (100× enlarged) or in 3D (150× enlarged; 0.5 μ m per z step). Photo-bleaching and crosstalk were excluded using a line-lambda scanning mode and sequencing laser excitation at 543, 488, and 405 nm. The confocal images were generated using EZ-C1 software (NIKON Corp., Tokyo, Japan).
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H&E Staining
For histopathological observations, portions of the ear tissue were fixed in 10% neutral-buffered formalin solution and then dehydrated in graded alcohol solutions. The fixed tissue was embedded in paraffin and sliced into 4-μm-thick sections. The tissue sections were mounted on regular glass slides, deparaffinized in xylene, rehydrated in decreasing concentrations of ethanol, and stained with hematoxylin and eosin (H&E).
Images Quantification Analysis
To evaluate the pathological parameters including ear thickness, number of infiltrating cells, protein expression, and phosphorylation levels, pictures were quantified using three low-power fields (10× or 20× objective) of each ear section (n = 3 per group) using Image-Pro Plus version 6.0 software (Media Cybernetics, Inc., Bethesda, MD). The object analyzed in each image was calibrated and quantified as described below. For ear thickness and epidermis thickness, we measured the average ear thickness in each low-power field directly. For number of infiltrating cells in each tissue, we first determined the optical RGB intensity range using fields from tissue from the TPA group and then established the appropriate standard RGB intensity range for each image of each cell marker. We then used the appropriate standard RGB intensity range for each cell marker to count the numbers of cells staining positively for CD45, CD3, Gr-1, CD54, IFN-γ, CD31, and Ki-67. For quantifying the level of phospho-GSK-3β Tyr216 (pGSK-3) and phospho-GS Ser641 (pGS), we used the same protocol to establish the standard RGB intensity range and then used the integrated optical density (IOD) as the level of pGSK-3 and pGS. The pGSK-3 IOD of each group divided by the average IOD of pGSK-3 of the PBS control group was used to calculate the activated GSK-3 index. We used the AOI (area of interest) mode to separate the epidermal-or dermal-expressed signal within each field. 
Short
Western Blotting
Harvested cells were lysed using a buffer containing 1% Triton X-100, 50 mM Tris (pH 7.5), 10 mM EDTA, 0.02% NaN 3 , and a protease inhibitor cocktail (Roche Boehringer Mannheim Diagnostics, Mannheim, Germany). Following one freeze-thaw cycle, the cell lysates were centrifuged at 12,000 rpm at 4°C for 20 min. Lysates were boiled in sample buffer for 5 min. Proteins were then subjected to SDS-PAGE and transferred to PVDF membranes (Millipore, Billerica, MA, USA) using a semi-dry electroblotting system. After blocking with 5% skim milk in PBS, membranes were incubated with a 1/1000 dilution of primary antibodies at 4°C overnight. Membranes were then washed using 0.05% PBS-Tween 20 and incubated with a 1/5000 dilution of horseradish peroxidase-conjugated secondary antibodies at room temperature for 1 h. After washing, membranes were soaked in an ECL solution (PerkinElmer Life Sciences Inc., Boston, MA, USA) for 1 min and then exposed to film (BioMax; Eastman Kodak, Rochester, NY, USA).
Luciferase Reporter Assay
For the luciferase reporter assay, the cells were transiently co-transfected using a
GeneJammer reagent (Stratagene) with an IRF1 promoter-driven luciferase reporter (0. 
Statistical Analysis
Values are expressed as the mean ± S.D. The groups were compared using Student's two-tailed unpaired t-tests or using a one-way ANOVAs in GraphPad Prism version 5. A value of p < 0.05 was considered to be statistically significant.
This article has not been copyedited and formatted. The final version may differ from this version. 76.3 ± 49.8, Ifngr1 -/-, P < 0.01, Fig. 1F ) and the expression of adhesion molecule CD54 (206.9 ± 78.6, wild type, vs. 125.1 ± 72.9, Ifngr1 -/-, p < 0.05, Fig. 1G ) but not the infiltration of CD3 + T cells (Fig. 1E) . These results indicate that IFN-γ signaling is essential for TPA-induced acute skin inflammation including edema, granulocyte infiltration, and CD54 expression but not T cell infiltration.
TPA Activates GSK-3 and Induces GSK-3-Regulated IFN-γ Signaling
We previously demonstrated that GSK-3 facilitates IFN-γ-STAT1 signaling (Tsai et al., 2009 ). We therefore hypothesized that GSK-3 facilitates TPA-induced acute skin inflammation. AEC-based immunohistochemistry ( Fig. 2A) showed that TPA-induced GSK-3 activation (1.0 ± 0.4, DMSO only, vs. 3.1 ± 1.9, TPA, p < 0.05, Fig. 2B ), which was detected as GSK-3β phosphorylation at Tyr216, an active residue of GSK-3β, and glycogen synthase phosphorylation at Ser641, a substrate of GSK-3, as shown previously (Tsai et al., 2011) , in the epidermis (1.4 ± 0.5, DMSO only, vs. 6.5 ± 3.1, TPA, p < 0.05, Fig. 2C ) and dermis (0.9 ± 0.4, DMSO only, vs. 4.2 ± 2.8, TPA, p < 0.05, Fig. 2D ). To verify the role of activated GSK-3, GSK-3 was inhibited using the inhibitor BIO, which binds within the ATP-binding pocket of GSK-3. The results showed that treatment with BIO (1.5 μ g per ear, the maximum dosage selected from three dilutions; data not shown), reduced TPA-induced STAT1 activation and expression in the epidermis but not the dermal infiltrate of wild type mice (Fig. 2E) . We next This article has not been copyedited and formatted. The final version may differ from this version.
JPET Fast Forward. Published on July 6, 2012 as DOI: 10.1124/jpet.112.194100 at ASPET Journals on July 6, 2017 jpet.aspetjournals.org Downloaded from investigated the role of GSK-3 in epidermal keratinocytes in response to IFN-γ. The expression of GSK-3α/β was knocked down in HaCaT human keratinocytes using a lentiviral-based shRNA approach (Fig. 2F) . A luciferase reporter assay for IRF1 promoter transactivation showed that the knockdown of GSK-3α/β, consistent with BIO (2.5 μ M) treatment, significantly (11.6 ± 5.2, DMSO only, vs. 5.2 ± 2.8, BIO, 5.5 ± 1.8, shGSK-3α, and 4.2 ± 1.3, shGSK-3β, p < 0.05) inhibited IFN-γ (10 ng ml -1 ) signaling (Fig. 2G ). These results demonstrate that TPA induces GSK-3 activation in the epidermis and leads to GSK-3 regulation of IFN-γ signaling. (Fig. 3D) . Thus, TPA induces the infiltration of granulocytes. The depletion of granulocytes, using an anti-Gr-1 antibody, suggests that granulocytes may be pathogenic in TPA-induced acute ear edema (Supplemental Figures 1B and C ). These results demonstrate that GSK-3 activation is pathogenic for TPA-induced acute skin inflammation including edema, granulocyte infiltration, and CD54 expression but not T cell infiltration.
GSK-3 Facilitates
Epidermal GSK-3 Facilitates TPA-Induced Edema and Granulocyte Infiltration
To further clarify the role of GSK-3 in epidermal keratinocytes in vivo, we created a local knockdown of GSK-3β using lentiviral-based shRNA interference in the ears of C57BL/6 mice. Our GSK-3β immunohistochemical results (Fig. 4A) show that GSK-3β knockdown reduces GSK-3β expression in the epidermis markedly (4.9 ± 1.5, shLuc, vs. 2.6 ± 0.9, shGSK-3β, p < 0.01, Fig. 4B ). Analysis of histological morphology (Fig. 4C ) revealed that the epidermal knockdown of GSK-3β significantly attenuated both TPA-induced ear edema (515.3 ± 73.6, shLuc, vs. 416.6 ± 39.9, shGSK-3β, p < 0.05, Fig. 4D ) and granulocyte infiltration (272.6 ± 88.6, shLuc, vs. 169.3 ± 61.0, shGSK-3β, p < 0.01, Fig. 4E ). These results imply that GSK-3 activation is key for TPA-induced edema and granulocyte infiltration.
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GSK-3 Facilitates TPA-Induced IFN-γ Production in CD3-Positive T Cells by Regulating T-bet Nuclear Translocation
The pathogenesis of immune-mediated psoriasis is thought to be T cell-mediated (Schon and Boehncke, 2005) . Our findings show that GSK-3-regulated IFN-γ signaling is not involved in CD3-positive T cell infiltration. Immunohistochemistry for IFN-γ (Fig. 5A) showed that TPA markedly induced IFN-γ production at 4 h (13.3 ± 7.8, DMSO only, vs. 37.1 ± 10.1, TPA, p < 0.001, Fig. 5B ) compared with the DMSO-treated group. However, treatment with BIO significantly (37.1 ± 10.1, TPA only, vs. 20.6 ± 7.2, TPA + BIO, p < 0.05) decreased TPA-induced dermal IFN-γ expression. GSK-3 is required for the nuclear translocation of T-bet (Hwang et al., 2005; Tsai et al., 2011) . Immunostaining and confocal image analysis identified TPA-induced GSK-3 activation, which was determined by the phosphorylation of GSK-3 at Tyr216 in CD3 positive T cells (Fig. 5C) . Notably, inhibiting GSK-3 decreased the TPA-induced T-bet nuclear translocation in CD3-positive T cells ( Fig.   5D and Supplemental Figure 2 ). These results demonstrate that GSK-3 activation in T cells facilitates IFN-γ production by facilitating T-bet nuclear translocation in TPA-induced acute skin inflammation.
GSK-3 Facilitates IFN-γ-Mediated Chronic TPA-Induced Psoriasis-Like Cutaneous
Inflammation
To further clarify the role of GSK-3 in skin inflammation, we also assessed the protective effects of GSK-3 inhibition in a model of chronic TPA treatment (Fig. 6A) . BIO treatment strikingly attenuated TPA-induced edema and epidermal swelling (Fig. 6B ), ear thickness (539.1 ± 119.7, TPA only, vs. 327.7 ± 51.1, TPA + BIO, p < 0.01, Fig. 6C ), and epidermal thickness (73.6 ± 15.1, TPA only, vs. 38.7 ± 4.6, TPA + BIO, p < 0.01, Fig. 6D ). To investigate the role of GSK-3 in IFN-γ-regulated chronic TPA-induced cutaneous inflammation, immunostaining of Ki-67, a proliferation marker, and CD31, an endothelial cell marker, were used (Supplemental Figure 3) . The results showed that inhibiting GSK-3 significantly suppressed TPA-induced epidermal cell proliferation (206.8 ± 66.3, TPA only, vs.
90.7 ± 44.2, TPA + BIO, p < 0.05, Fig. 6E ) and dermal angiogenesis (89.0 ± 28.1, TPA only, vs. 25.0 ± 12.5, TPA + BIO, p < 0.01, Fig. 6F ). Immunostaining showed that chronic TPA treatment also induced GSK-3 activation (Fig. 6G ). These results demonstrate that inhibiting GSK-3 attenuates chronic TPA-induced cutaneous inflammation including edema, epidermal proliferation, and angiogenesis. ). We further demonstrate that depletion of granulocytes causes a decrease in TPA-induced acute ear edema. We speculate that T cell activation and granulocyte infiltration facilitates TPA-induced skin inflammation.
IFN-γ is an important pro-inflammatory cytokine for several types of psoriasis (Szegedi et al., 2003; Yao et al., 2008; Abdallah et al., 2009; Takahashi et al., 2010) . To the best of our knowledge, this study provides the first evidence showing that IFNGR1 is required for This article has not been copyedited and formatted. The final version may differ from this version.
JPET Fast Forward. Published on July 6, 2012 as DOI: 10.1124/jpet.112.194100 at ASPET Journals on July 6, 2017 jpet.aspetjournals.org Downloaded from TPA-induced skin inflammation. We speculate that these findings may explain the effects of aberrant IFN-γ production (Szegedi et al., 2003; Abdallah et al., 2009; Takahashi et al., 2010) and STAT1 activation in psoriatic lesions (Yao et al., 2008) . Notably, inhibiting GSK-3 with BIO or lentiviral-based GSK-3β-targeted shRNA resulted in an inhibition of the TPA-induced skin inflammation. Mechanistically, GSK-3 not only facilitates IFN-γ signaling in keratinocytes but is also required for TPA-induced IFN-γ production independent of the interference with T cell infiltration. These findings are consistent with recent studies that suggest that GSK-3 facilitates IFN-γ-mediated inflammation by activating STAT1 (Tsai et al., 2009 ). Additionally, GSK-3 facilities Con A- (Tsai et al., 2011) and TPA-induced IFN-γ-mediated inflammatory activation by promoting STAT1 activation and the nuclear translocation of T-bet, which results in an increase in IFN-γ production. In addition to IFN-γ, the role of Th17 cell activation and differentiation in GSK-3 activation requires further investigation (Beurel et al., 2011) . The role of Th17 responses in TPA-induced skin inflammation also requires further investigation. In addition to Th1-IFN-γ-mediated skin inflammation, we speculate that inhibiting GSK-3 may also reduce Th17 responses.
Treatment with TPA induces GSK-3β activation in epidermal keratinocytes and infiltrated T cells. A limitation of this study is that is remains unclear whether TPA induces GSK-3 activation directly or indirectly through other mechanisms, such as damage-associated molecules. Previous studies suggest that the activation of GSK-3 by IFN-γ, IL-6, and GM-CSF facilitates the activation of STAT1, 3, 5, and 6 (Tsai et al., 2009; Wang et al., 2011) . It is therefore hypothesized that these cytokines determine TPA-mediated GSK-3 activation and could induce IFN-γ, IL-6, and GM-CSF expression (Oberg et al., 2001) . Consistent with our previous studies (Lin et al., 2008; Tsai et al., 2009; Kai et al., 2010) and those of others (Beurel et al., 2010; Wang et al., 2011) , treatment with IFN-γ causes GSK-3 activation followed by GSK-3-mediated STAT1 activation. We further verified that the molecular mechanism underlying IFN-γ-activated GSK-3 is the triggering of bioactive sphingolipid ceramide-mediated pathways (Tsai et al., 2009; Wang et al., 2011) . We therefore hypothesize that the activation of GSK-3 by ceramide may be involved in TPA-activation of T cells and IFN-γ-activated keratinocytes. The involvement of ceramide signaling in TPA-induced skin inflammation requires further investigation. In addition to GSK-3β, knockdown of GSK-3α, which is a functionally redundant GSK-3 under some conditions (Beurel et al., 2010; Wang et al., 2011) , also reduced IFN-γ signaling. Essentially, the pharmacological inhibition of GSK-3 by BIO did not exclude the involvement of GSK-3α, and it is possible that GSK-3α
This article has not been copyedited and formatted. The final version may differ from this version. In conclusion, our study demonstrates that the inhibition of GSK-3 not only blocks IFN-γ production but also reduces IFN-γ-mediated STAT1 activation and inflammatory responses.
Our results suggest that inhibiting GSK-3 using pharmacological or genetic manipulations is a potential therapeutic strategy for IFN-γ-mediated skin inflammation not only via the inhibition of IFN-γ production but also the blockade of IFN-γ signaling, granulocyte infiltration, CD54 expression, edema, epidermal hyperplasia, and angiogenesis. The findings of this study may provide insight for future pre-clinical or clinical studies that use more comparable models of IFN-γ-and GSK-3-mediated human skin diseases.
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